The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system
- 1 January 2001
- journal article
- Published by Wiley in Haemophilia
- Vol. 7 (1), 82-88
- https://doi.org/10.1111/j.1365-2516.2001.00457.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Why do inhibitors arise in patients with haemophilia A?British Journal of Haematology, 1999
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999
- Occurrence of hemophilia in the United StatesAmerican Journal of Hematology, 1998
- A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of CanadaThrombosis and Haemostasis, 1998
- Recommendations for the treatment of factor VIII inhibitorsBlood Coagulation & Fibrinolysis, 1996
- The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentratesTransfusion, 1995
- Epidemiology of hemophilia and of HIV infection in ItalyJournal of Clinical Epidemiology, 1994
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance ProjectTransfusion, 1992
- Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.BMJ, 1983